Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study

Eun-Seok Shin1, Hector M Garcia-Garcia, Takayuki Okamura

  • 1Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. ses@uuh.ulsan.kr

Insights

Statins reduced overall plaque volume in coronary arteries. Rosuvastatin halted necrotic core progression, unlike simvastatin, suggesting differential effects on vulnerable plaque components.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Pharmacology

Background:

  • Coronary bifurcation atherosclerosis affects non-culprit vessels.
  • Intravascular ultrasound virtual histology (VH-IVUS) assesses plaque composition.
  • Statins are used to manage atherosclerosis.

Purpose of the Study:

  • To assess the effect of simvastatin versus rosuvastatin on coronary bifurcation atherosclerosis in non-culprit vessels using VH-IVUS.
  • To evaluate changes in plaque volume and composition after 12 months of statin therapy.

Main Methods:

  • Non-randomized study of 48 patients with 51 bifurcation sites.
  • Baseline and 12-month follow-up VH-IVUS analysis.
  • Treatment with simvastatin (20 mg) or rosuvastatin (10 mg) daily.

Main Results:

  • Overall plaque and external elastic membrane volume decreased.
  • Dense calcium volume increased, while fibrous and fibrofatty volumes decreased.
  • Necrotic core volume did not change significantly overall, but increased with simvastatin and remained stable with rosuvastatin.

Conclusions:

  • Statin therapy leads to favorable plaque remodeling and compositional changes in non-culprit coronary artery bifurcations.
  • Rosuvastatin demonstrated a potential benefit in halting necrotic core progression compared to simvastatin.
  • Changes in HDL-cholesterol and hsCRP levels predicted reduction in necrotic core volume.

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...